Cytek Biosciences (CTKB) AI Stock Analysis

• Market Cap: $557.49M
• Dividend Yield: N/A
• Average Volume (3M): 745.79K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.35
• Revenue Growth: -2.18%
• EPS Growth: -30.96%
• Country: US
• Employees: 663
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.30
• Shares Outstanding: 127,864,830
• 10 Day Avg. Volume: 553,190
• 30 Day Avg. Volume: 745,792
• PEG Ratio: >-0.01
• Price to Book (P/B): 1.89
• Price to Sales (P/S): 3.20
• P/FCF Ratio: -73.56
• Enterprise Value/Market Cap: 0.89
• Enterprise Value/Revenue: 2.46
• Enterprise Value/Gross Profit: 4.75
• Enterprise Value/Ebitda: -23.32
• 1Y Price Target: $6.17
• Price Target Upside: 40.23% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): -0.14
• Revenue Forecast (FY): $207.38M

• Rating: 52 Neutral
• Price Target: $4.50 ▲(2.27% Upside)
• Action: Reiterated Date: 02/27/26
• Date: Action: Reiterated 02/27/26

The score is held back primarily by deteriorating profitability and inconsistent cash generation, reinforced by weak technical momentum. These are partially offset by a strong low-debt balance sheet and an earnings call that points to modest growth and continued positive adjusted EBITDA, driven by recurring revenue and installed base expansion, despite margin and cost headwinds.

Positive Factors

Balance sheet strength

Extremely low leverage (debt-to-equity ~0.04) and a cash-rich position give Cytek durable financial flexibility to fund R&D, support the manufacturing transition, underwrite operating volatility, and pursue strategic initiatives without reliance on new debt over the next several quarters.

Recurring revenue expansion

Recurring lines (service, reagents, software) now comprise a material and growing portion of sales (34%, +21% YoY). That recurring mix increases revenue visibility, improves lifetime customer value, and supports margin stability over time as the installed base and cross-sell deepen.

Installed base and unit momentum

Added 208 instruments in Q4 and 3,664 total installed units (22% unit growth) creates a structural driver for consumables, service contracts, and software adoption. A larger installed base supports sustainable pull-through revenue and customer stickiness over multiple quarters.

Negative Factors

Gross margin compression

Material margin erosion—GAAP gross margin fell notably year-over-year—reflects higher materials, tariffs, and duplicate manufacturing costs during an overseas transition. These structural cost pressures can persist and constrain long-term profitability until supply-chain or pricing improvements are realized.

Volatile cash generation

Operating and free cash flow swings undermine predictability: a strong 2024 flipped to negative in 2025. This inconsistency weakens the company’s ability to fund growth, absorb shocks, or sustainably finance buybacks and investments without tapping reserves or altering strategy.

Deteriorating profitability and expense pressures

Large GAAP losses, amplified by a substantial deferred tax valuation allowance, plus rising operating expenses and legal costs, indicate weakened earnings power. Persistent negative net income and elevated OPEX reduce reinvestment capacity and prolong the timeline to consistent GAAP profitability.

Cytek Biosciences Business Overview & Revenue Model

Company Description

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system, which leverages full spectrum profiling technology to further broaden potential applications across cell analysis. The company also provides reagents and kits, including cFluor reagents, which are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, which are automated plate loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific region; and through distributors or sales agents in European, Latin American, the Middle Eastern, and the Asia-Pacific countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.

How the Company Makes Money

Cytek Biosciences generates revenue primarily through the sale of its flow cytometry instruments, reagents, and related consumables. The company’s revenue model is based on a combination of product sales and recurring revenue from consumables and service contracts. Key revenue streams include direct sales of the Aurora and Northern Lights systems, which are marketed to research institutions, clinical laboratories, and pharmaceutical companies. Additionally, Cytek benefits from partnerships with other biotech and pharmaceutical firms that may involve joint development initiatives or co-marketing agreements, further enhancing its market reach and revenue potential.

Cytek Biosciences Financial Statement Overview

Summary

Balance sheet strength (very low leverage) supports resilience, but operating results are weak: revenue growth has slowed to low single digits, losses widened sharply in 2025, and cash flow flipped back to negative after a strong 2024.

Income Statement

Revenue growth has slowed materially over time (from ~60% in 2020 to ~0% in 2024, then ~2% in 2025), while profitability has deteriorated. Gross margin remains solid (~52% in 2025), but operating performance is weak with ongoing losses and a sharp step-down in net margin (about -3% in 2024 to about -33% in 2025). Overall, the top line is relatively stable, but the company has not translated that into sustainable earnings and saw a meaningful setback in the latest year.

Balance Sheet

The balance sheet is a clear strength: leverage is low and consistent (debt-to-equity ~0.04 in 2023–2025), providing flexibility. However, equity has declined from 2022 to 2025, and returns on equity are negative in recent years, reflecting that losses are eroding shareholder value. Net: financially resilient structure with limited debt risk, but weakening equity trajectory tied to profitability challenges.

Cash Flow

Cash generation is volatile. The company produced strong positive operating and free cash flow in 2024, but both turned negative again in 2025, which raises questions about consistency of underlying cash earnings. Free cash flow growth appears high in 2024–2025, but that is influenced by large swings year-to-year (including negative periods), so the trend is not yet reliable. Overall, cash flow performance is mixed and less dependable than the balance sheet.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	201.49M	200.45M	193.01M	164.04M	127.95M
Gross Profit	104.46M	111.11M	109.43M	100.97M	79.14M
EBITDA	-40.38M	-10.03M	-4.41M	9.49M	8.92M
Net Income	-66.54M	-6.02M	-12.15M	2.58M	3.00M
Balance Sheet
Total Assets	461.54M	499.50M	494.46M	519.48M	463.31M
Cash, Cash Equivalents and Short-Term Investments	261.53M	277.86M	262.41M	341.15M	364.62M
Total Debt	14.04M	17.02M	14.14M	18.09M	0.00
Total Liabilities	119.80M	103.76M	101.39M	93.93M	57.92M
Stockholders Equity	341.74M	395.74M	393.06M	425.30M	405.04M
Cash Flow
Free Cash Flow	-8.77M	21.85M	454.00K	-22.10M	266.00K
Operating Cash Flow	-4.69M	25.38M	5.28M	-12.23M	4.63M
Investing Cash Flow	10.12M	-82.97M	-93.89M	-55.91M	-20.99M
Financing Cash Flow	-13.43M	-15.82M	-41.81M	5.51M	213.56M

Cytek Biosciences Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 4.40
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CTKB, the sentiment is Neutral. The current price of 4.4 is below the 20-day moving average (MA) of 4.52, below the 50-day MA of 4.94, and above the 200-day MA of 4.14, indicating a neutral trend. The MACD of -0.20 indicates Negative momentum. The RSI at 39.91 is Neutral, neither overbought nor oversold. The STOCH value of 75.51 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CTKB.

Cytek Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BVS	64 Neutral	$721.70M	77.92	4.97%	―	1.58%	―
SIBN	56 Neutral	$663.45M	-35.75	-12.91%	―	23.27%	43.90%
BFLY	55 Neutral	$745.18M	―	-41.42%	―	16.04%	28.91%
CTKB	52 Neutral	$557.49M	-43.22	-3.36%	―	-2.18%	-30.96%
VREX	52 Neutral	$564.39M	-8.19	-13.95%	―	4.14%	-45.29%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PACB	46 Neutral	$501.17M	-0.89	-213.45%	―	-10.72%	-16.00%